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Background: The REnal Protection Against Ischaemia Reperfusion in transplantation (REPAIR) study 
examined the utility of remote ischaemic preconditioning (RIPC) prior toliving donor kidney transplantation. 
The primary endpoint, GFR at 12 months, although statistically not significant, suggested the potential for 
RIPC to improve kidney function. A key secondary endpoint, CKD-EPI eGFR collected from site reported 
creatinine values, demonstrated significant potential to improve eGFR at 3 months and 1 year. Here we 
present eGFR collected yearly, up to 5 years following transplantation.  
Methods: In this double blind randomised controlled trial we enrolled 406 adult live donor kidney 
transplant donor-recipient pairs at kidney transplant centres in the UK and Europe. Pairs were randomised 
using a factorial design to: sham RIPC, early RIPC only (immediately pre-surgery), late RIPC only (24 hours 
pre-surgery) or dual RIPC (early and late RIPC). RIPC consisted of 4x5-minute inflations of a blood pressure 
cuff on the upper arm to 40 mmHg above systolic blood pressure separated by 5-minute periods of cuff 
deflation. For sham RIPC low pressure inflations of 40 mmHg were used. Importantly, the intervention was 
performed prior to anaesthetic induction.  
Results: There was a sustained improvement in eGFR with early RIPC compared to control from 3 months 
to 5 years (adjusted mean difference 4.71 ml/min/1.73m2; 95% CI 1.54 to 7.89; p=0.004). Observed 
mortality or graft loss was lower with RIPC, confirming safety. 
Conclusions: RIPC is safe (as demonstrated in this study), and when administered prior to anaesthetic 
induction improves long term kidney function following living donor transplantation.   
Trial Registration: ISRCTN30083294. 
Full protocol available at: www.lshtm.ac.uk/repair 
 









Kidney transplantation is the optimal treatment for suitable patients with end-stage renal disease (ESRD)1. 
However, a shortage of donors and eventual failure of the allograft means that many patients require 
dialysis for long-term therapy. During surgery, the kidney sustains ischaemic damage between interruption 
of its blood supply in the donor and reperfusion in the recipient. Reperfusion causes a second injury, and 
this composite ischaemia-reperfusion injury (IR injury) determines the function of the transplanted kidney 
in the immediate post-operative period and may increase the risk of acute and chronic rejection.2 Reducing 
IR injury to the kidney should result in a healthier kidney at implantation, and ultimately one with a longer 
lifespan.  
 
One method of rendering organs resistant to IR injury is ischaemic preconditioning (IPC), which utilises sub-
lethal ischaemia (preconditioning stimulus) to induce a state of protection against subsequent prolonged 
ischaemia.3 This protection is biphasic; an early phase occurs within minutes of the preconditioning 
stimulus (lasting for up to four hours) and a late phase occurs 24 hours after the preconditioning stimulus 
(lasting for up to 72 hours).4,5,6 The difficulties of directly applying IPC stimuli to vital organs in humans has 
precluded its assessment in adequately powered clinical trials. However preconditioning has a systemic 
phenotype (remote ischaemic preconditioning; RIPC), and this facet of preconditioning could protect 
against IR injury to the kidney.7 RIPC is activated by brief periods of ischaemia to a limb, and a number of 
small-scale clinical studies have demonstrated potentially protective effects in humans.8.  
 
The REnal Protection Against Ischaemia-Reperfusion in transplantation (REPAIR) trial suggested there is 
potential for early RIPC to improve kidney function one year after transplant.9 REPAIR found little evidence 
of an effect of late RIPC but there was a suggestion that early RIPC improved iohexol glomerular filtration 
rate (GFR) (difference in mean GFR 3.08 ml/min/1.73m2; 95% CI -0.89 to 7.04; p=0.13) and better evidence 
of a benefit on estimated (e)GFR using centrally measured creatinine at the time of the Iohexol test 
(difference in means 4.98 ml/min/1.73m2; 95% CI 1.13 to 8.83; p=0.011). There were no major safety 
concerns around RIPC, although as expected RIPC caused transient pain/paraesthesia and minor petechiae 
related to cuff inflation. It is important to note that the mechanism of RIPC has not been fully elucidated, 
and anaesthetic agents have been implicated in both potentiating10 and abrogating11 RIPC. Therefore in this 
study, we elected to deliver RIPC prior to the induction of anaesthetic agents, hence allowing activation of 
this innate protective reflex prior to administration of potentially confounding agents.  
 
In this paper, we report clinical outcomes up to 5 years of recipients enrolled in REPAIR – eGFR (Chronic 








Study design and participants 
REPAIR was a multi-centre factorial double-blind randomised controlled trial assessing the impact of RIPC 
on kidney function following live donor kidney transplantation. Full details of the study design have 
previously been reported.9 In brief, 406 pairs of transplant recipients and donors were recruited from 
kidney transplant centres in the UK, the Netherlands, Belgium and France. Patients were excluded who 
were aged <18 years, on medicines that modulate preconditioning pathways (ATP-sensitive potassium 
channel opening or blocking drugs, or ciclosporin), had iodine sensitivity (contraindicating iohexol), or 
required antibody removal  (ABO or HLA incompatible transplants). 
Ethical approval for the study in the UK was given by the Joint University College London/University College 
London Hospitals Committees on the Ethics of Human Research (Reference number: 09/H0715/48) and by 
local Research Ethics Committees for sites outside the UK. REPAIR was registered with the International 
Standard Randomised Controlled Trial Register (ISRCTN; reference number 300832940).  
Randomisation and blinding 
Recipients and donors were randomised equally to control (sham RIPC), early RIPC alone (immediately pre-
surgery), late RIPC alone (24 hours pre-surgery) and dual RIPC (RIPC 24 hours and immediately pre-surgery) 
groups. Donor and recipient were randomised to the same intervention group. Randomisation was by a 
web-based service with random permuted blocks stratified by centre. Unblinded research staff not involved 
in sample collection or data analysis performed enrolment and preconditioning procedures. All other 
research personnel at each centre, including those responsible for assessing outcomes, remained blinded 
to treatment allocation. 
 
Procedures 
The active RIPC procedure consisted of four, five-minute inflations of a blood pressure cuff on the upper 
arm to 40 mmHg above systolic blood pressure, separated by five-minute periods of cuff deflation. The 
sham RIPC procedure consisted of four five-minute inflations on the upper arm to 40 mmHg separated by 
five-minute periods of cuff deflation. Active or sham RIPC sequences were completed before administration 
of anaesthetic agents. Donors were followed up to day three post-transplant and recipients up to 5 years 
post-transplant. 
Outcomes 
The primary outcome (iohexol GFR at 12 months) has already been reported.9  In this paper we focus on 
the pre-specified secondary outcomes of eGFR at three months, 12 months, and then annually up to 5 






site reported serum creatinine measures using the CKD-EPI formula.10 We also report graft and patient 
outcomes up to 5 years, another pre-specified secondary outcome in this study.  
 
Statistical analysis 
The effect of RIPC on eGFR over all follow-up visits (at three, 12 months, and 2-5 years after 
transplantation) was examined using a linear mixed effects model for repeated measures with indicator 
variables for early RIPC, late RIPC and time of visit. This analysis includes all four of the randomised groups, 
with those received dual RIPC included in both the early RIPC vs sham and the late RIPC vs sham 
comparisons. An unstructured residual variance–covariance matrix allowed for the anticipated correlation 
between repeated measures of eGFR on the same patient. A second mixed effects model evaluated the 
treatment effects at each follow-up time point by including an interaction between treatment and visit. 
This model was used to predict the average eGFR by treatment group at each visit. 
A large interaction between early and late RIPC on mean GFR was not expected and the trial was under-
powered to detect small interactions. However, this was formally tested by including an interaction term 
between early and late RIPC. Irrespective of the result of the interaction tests, a linear mixed effects model 
was used to compare eGFR between the combined RIPC arms (early, late and dual) and the arm receiving 
no RIPC. All analyses adjusted for the donor’s baseline eGFR. 
For patients with a missing eGFR due to death or graft loss, a value of 0 was imputed, and the impact of this 
was tested in a secondary sensitivity analysis. Data were included from all patients who had an eGFR 
measure at one or more of the visits (or had 0 imputed for death or graft loss), providing an unbiased 
estimate of the treatment effect under the assumption that data were missing at random given the pattern 
of eGFR at the other time points, treatment group and donor eGFR. The distribution of eGFR was examined 
to assess whether any transformations were necessary in order to adhere to the assumptions of the 
analysis models. 
Graft survival and mortality up to 5 years post transplant were compared between treatment groups using 
Kaplan-Meier plots and a Cox proportional hazards regression model with indicator variables for early RIPC 
and late RIPC. In view of the small numbers of events observed, graft loss and mortality were combined 
into a single endpoint as an additional analysis to that stated in the Statistical Analysis Plan. All primary 
analyses were intention to treat, and a secondary per protocol analysis was also undertaken. Stata version 









Between January 2010 and April 2013, 406 donor recipient pairs were randomised:  99 to sham RIPC; 102 
to early RIPC; 103 to late RIPC; and 102 to dual RIPC. The baseline characteristics were reasonably well-
balanced across the four treatment arms at baseline (Table 1).  By end of May 2018 all patients had 
reached 5 years of follow-up. At 1 year, information was available for 96% of patients. The corresponding 
percentages for 2, 3, 4 and 5 years were 95%, 91%, 88% and 93% respectively, with follow-up completion 
similar across the trial arms (eFigure 1). Data from 2-5 years follow-up are reported here for the first time. 
 
Effect of RIPC on GFR 
There was strong evidence that mean eGFR up to 5 years post-transplant was higher in the early RIPC group 
compared to control (adjusted difference in mean eGFR=4.71 ml/min/1.73m2; 95% confidence interval (CI) 
1.54 to 7.89; p=0.004) and little evidence of a benefit of late RIPC (adjusted difference in mean eGFR=1.35; 
95% CI: -1.83 to 4.53; p=0.41) (Table 2). There was no evidence of an interaction between early and late 
RIPC (p=0.91). However, the results indicated a clinically important benefit of combined RIPC arms (early, 
late and dual) compared to no RIPC (eTable 1). 
 
There was no evidence that the effect of early RIPC differed by visit (p=0.78 interaction test) or that the 
effect of late RIPC differed by visit (p=0.36). Further, when the treatment effect was estimated for each visit 
from 3 months up to five years after transplantation, eGFR was consistently higher in the early RIPC group 
than in the control group (Figure 1A, Table 2). There was a lag of at least 2 years for the mean eGFR in the 
early RIPC arm to reduce to that in the control arm. At each visit the mean eGFR was higher in the late RIPC 
group than in the control group although the evidence for a treatment effect was weak (Figure 1B, Table 2). 
 
Results were similar from a sensitivity analysis without imputation of 0 eGFR for patients with graft loss or 
death (eTable 2). The adjusted mean difference between early RIPC and control was 4.50 (95% CI 1.57 to 
7.43; p=0.003) and the adjusted mean difference between late RIPC and control was 1.49; (95% CI -1.44 to 
4.42; p=0.32).  
 
Results from the per-protocol analysis of 362 donor recipient pairs (89% of 406 randomised pairs), after 
excluding those pairs where the intervention was not undertaken or incomplete, were very similar 
(eTable 3). There was evidence for higher mean eGFR with early RIPC compared to control, which was 








Effect of RIPC on graft loss and mortality 
Up to 5 years, 23 patients had experienced graft loss and 21 patients had died, figures consistent with 
transplant registry data in the UK.13 The proportion with these outcomes was numerically lower amongst 
those who had received early RIPC or late RIPC compared to the control group, but the study was 
underpowered to detect differences in these endpoints (Table 2; Figure 2; eTable 4; eFigure 2, eFigure 3). 
However, the data on mortality do not raise any concerns about the safety of RIPC and the only apparent 
adverse events were the previously reported transient pain/paraesthesia at the time of preconditioning, 









REPAIR is the largest phase 3 clinical trial to estimate the effect of RIPC on clinically relevant end-points in 
kidney transplantation and has over 90% completeness for long term (5 year) follow-up. Although there 
was some evidence for an effect of RIPC on iohexol-measured GFR at 1 year (primary outcome of the 
trial),there was good evidence for an effect on eGFR at both 3 months and 1 year. This paper reports the 
sustained benefit  over 5 years of follow-up. This benefit was observed in those recipients who had 
undergone preconditioning immediately pre-transplant i.e. ‘early’ RIPC, either alone or in combination with 
delayed (‘late’) preconditioning. There was no evidence of an effect of delayed (‘late’) preconditioning on 
kidney function, although results do not rule out a small benefit over the longer term. RIPC had minimal 
morbidity, no serious or sustained adverse effects, and was low cost and of little inconvenience to patients.  
 
The discovery that limb ischaemia activates a whole-body systemic reflex that may limit tissue injury to vital 
organs in animals and humans7 has stimulated a large number of clinical trials to detect clinically 
meaningful protective effects. There have been several previous studies in kidney transplantation, which 
have shown heterogeneity in the way in which ischaemic conditioning has been applied.14 Most were small 
studies that were not powered to detect differences on clinical endpoints, which is likely to have 
contributed to the heterogeneity in their findings. The largest previous study to date, of 225 recipients of 
deceased donor kidney transplantation, did not find a benefit of preconditioning.15 However, there were 
important differences in the preconditioning protocol;  preconditioning was given to recipients only and 
performed after initiation of anaesthetic while we preconditioned both donor and recipient prior to 
initiation of anaesthetic. Additionally the heterogeneity in the clinical phenotypes of deceased donors 
would suggest that a much greater sample size would be necessary to infer any conclusions in the clinical 
trial setting, and that clinical trial outcomes of cadaveric and live donors cannot be directly compared. 
 
It is well documented in the literature that the volatile anaesthetic agents can pharmacologically mimic the 
effects of RIPC, so-called ‘anaesthetic preconditioning’.9 It was with this in mind that we elected to perform 
RIPC in advance of any anaesthetic being administered. Patients who undergo kidney transplantation 
typically receive induction with propofol and maintenance with volatile anaesthetic agents, and a survey of 
a random subset of 4 centres in REPAIR confirmed this practice. Since the initial results of REPAIR were 
published, it is now understood that propofol can inhibit RIPC.10 This has been postulated as the reason 
why large studies in cardiac surgery utilising propofol anaesthesia, most notably the ERICCA study16 of over 
1600 patients, demonstrated no effect of RIPC, whilst studies such as that by Zarbock et al.17, who avoided 
propofol, demonstrated that RIPC was effective, both in reducing cardiac injury but also in reducing the 
incidence of acute kidney injury (AKI). It is important to note that RIPC can cause some discomfort, and 






needed, in order to determine if RIPC could be delivered during anaesthetic to minimise this discomfort. It 
should be noted that in the setting of kidney transplantation we chose not to extend the relatively short 
anaesthetic time by 30 minutes to facilitate RIPC; clearly in areas such as cardiac surgery it would be 
pertinent that this approach could be considered whilst the patient is being set up for surgery. Additionally, 
performing RIPC during anaesthetic would maintain true ‘blindedness’ in any clinical study.  
 
In many ways, live donor kidney transplantation is an ideal model for investigating RIPC. Surgery is carefully 
scheduled, and this facilitates the application of a preconditioning stimulus before surgery and prior to the 
administration of a general anaesthetic. This enables the early and late effects of preconditioning to be 
tested in the presence of intact neuro-hormonal reflexes, conditions that are likely necessary to optimally 
activate protection.18 Preconditioning both donors and recipients ensures that the donor kidney undergoes 
preconditioning in advance of its ischaemic insult, as well as potentially modulating the reperfusion injury 
in the recipient. In addition, live donor kidney ischaemia times are relatively consistent, which reduces the 
variability of kidney injury and kidney function after surgery and improves the ability to detect an effect of 
RIPC.   
 
REPAIR used plasma clearance of iohexol (a direct measure of glomerular filtration) to measure GFR at 12 
months, which constituted the primary endpoint of the trial. However, the observed variation of iohexol 
clearance was greater than expected, due to the greater complexity of the Iohexol test and the potential 
for human error in administering the full dose and in accurately documenting the timing of the subsequent 
blood samples. Variability in the Iohexol results may have been one of the reasons that we were unable to 
demonstrate evidence of an effect of early RIPC on GFR despite the consistency of the estimated impact 
shown by the different methods and over follow-up. 
 
In light of the lack of a robust demonstration of the effects of early RIPC on GFR at 12 months, it is the data 
beyond 12 months that give confidence in the protective effect of early RIPC in renal transplantation. For 
pragmatic reasons, eGFR (CKD-EPI formula) was used as the measure of graft function during the 5 year 
follow up. This simpler measure, which is routinely performed at all clinic visits, could be collected easily 
and without expense, thus ensuring a more complete dataset – data were obtained from up to 95% of 
available patients at each time point. Between 12 months and five years, eGFR remained approximately 
10% higher in the group randomised to early RIPC. The effect on eGFR when using site reported creatinine 
was similar to the effect we previously reported for centralised analyses of serum creatinine at 12 months,9 
which further supports the reliability of the long-term findings. In fact, when centrally measured creatinine 
was used at 12 months the treatment effect was larger and more precise (4.98; 1.13 to 8.83; p=0.011) 







There are around 28,000 patients on dialysis (hemo- or peritoneal dialysis) in the UK,19 with a median 
waiting time of approximately 2.3 years for the deceased donor kidneys that become available for 
transplantation every year11. There is significant morbidity and annual mortality among prevalent 
haemodialysis patients19. Dialysis also imposes substantial and permanent restrictions on lifestyle and has 
substantial economic costs11,19. Therefore, approaches that maximise the lifespan of each transplanted 
kidney will benefit patients directly, contribute to a reduction in the transplant list and moderate the costs 
of renal replacement therapy. Given the current annual rate of decline of eGFR after kidney transplantation 
in the UK of  0.7 ml/min/1.73m2,19 a patient starting out after transplantation with a 5ml/min/1.73m2 
advantage might expect several years of extension to the lifespan of the transplant. The cost of this 
intervention amounts to no more than a 40-minute procedure that causes a transient unpleasant 
sensation. A single, phase 3 trial does not usually change medical practice, and therefore there is an urgent 
need for further well designed clinical studies in this area. 
 
CONCLUSION 
REPAIR demonstrates that RIPC causes a clinically meaningful enhancement of kidney allograft function 
following live donor transplantation over five years of follow-up, with the likelihood that RIPC extends the 
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Table 1: Baseline characteristics of recipients and donors, by treatment group 
 Control (N=99) Early RIPC (N=102) Late RIPC (N=103) Dual RIPC (N=102) 
N with baseline data 95 98 99 99 
Recipient male, N (%) 58 (61·1) 71 (72·4) 65 (65·7) 73 (73·7) 
Donor male, N (%) 41 (43·2) 47 (48·0) 47 (47·5) 41 (41·4) 
Recipient ethnicity, N (%)     
  White 76 (80·0) 81 (82·7) 86 (86·9) 78 (78·8) 
  Asian 5 (5·3) 8 (8·2) 4 (4·0) 6 (6·1) 
  Black 5 (5·3) 5 (5·1) 5 (5·1) 11 (11·1) 
  Other 6 (6·3) 3 (3·1) 4 (4·0) 2 (2·0) 
  Not stated 3 (3·2) 1 (1·0) 0 (0) 2 (2·0) 
Donor ethnicity, N (%)     
  White 78 (82·1) 75 (76·5) 85 (85·9) 81 (81·8) 
  Asian 3 (3·2) 10 (10·2) 4 (4·0) 4 (4·0) 
  Black 5 (5·3) 5 (5·1) 4 (4·0) 10 (10·1) 
  Other 5 (5·3) 4 (4·1) 4 (4·0) 3 (3·0) 
  Not stated 4 (4·2) 4 (4·1) 2 (2·0) 1 (1·0) 




47·6 (18,77) 45·9 (18,76) 45·3 (19,72) 
Donor age, mean (range), years 50·2 (20,77) 50·8 (22,77) 49·1 (22,77) 49·2 (22,75) 
Recipient BMI, mean (SD),  
kg/m2* 
26·3 (4·9) 26·2 (4·7) 25·5 (4·2) 24·8 (4·4) 
Donor BMI, mean (SD),  kg/m2* 25·9 (3·2) 26·8 (4·0) 25·2 (4·0) 26·5 (3·9) 
Recipient systolic BP, mean (SD), 
mmHg* 
132 (19·0) 138 (19·0) 133 (19·7) 133 (15·3) 
Donor systolic BP, mean (SD), 
mmHg* 
122 (13·3) 126 (15·6) 126 (15·5) 124 (15·3) 
Recipient creatinine, mean (SD), 
µmol/L 
635 (292·6) 607 (256·1) 622 (296·7) 643 (261·4) 
Donor creatinine, mean (SD), 
µmol/L 
71 (13·2) 73 (15·9) 73 (16·9) 75 (16·5) 
Donor GFR (mL/min per 1·73 m2) 96·3 (13·0) 95·1 (16·4) 95·5 (15·5) 93·3 (16·8) 
     
Donor medical history, N (%)     
  Previous kidney transplant** 8 (8·1) 5 (4·9) 6 (5·8) 10 (9·8) 
  Dialysis prior to transplant 51 (53·7) 51 (52·0) 46 (46·5) 57 (57·6) 
  Glomerulonephritis 19 (20·0) 18 (18·4) 13 (13·1) 17 (17·2) 
     -biopsy proven 13 (13·7) 13 (13·3) 10 (10·1) 16 (16·2) 
  Pyelonephritis 3 (3·2) 2 (2·0) 4 (4·0) 2 (2·0) 
  Diabetes 11 (11·6) 13 (13·3) 6 (6·1) 7 (7·1) 
  Polycystic Kidney 13 (13·7) 12 (12·2) 18 (18·2) 13 (13·1) 
  Hypertension 31 (32·6) 41 (41·8) 38 (38·4) 48 (48·5) 
  Renal vascular disease 1 (1·1) 2 (2·0) 4 (4·0) 2 (2·0) 
  Aetiology uncertain 7 (7·4) 6 (6·1) 7 (7·1) 7 (7·1) 
  Other diagnoses 47 (49·5) 49 (50·0) 54 (54·5) 53 (53·5) 
Abbreviations: N, number; SD, standard deviation; BMI, body mass index; BP, blood pressure; GFR, 
glomerular filtration rate. 
*These characteristics were recorded for fewer than the 391 participants who had baseline data: 
recipient BMI n=389, donor BMI n=356, recipient systolic BP n=389, donor systolic BP n=388. 







Table 2: Effect of RIPC on eGFR (ml/min/1.73m2), graft loss and death up to 5 years post-transplant, 
intention to treat analysis 
 
Outcome Control (N=202) Early RIPC (N=204) Difference in means 
(95% CI)* 
P-value 
N Mean (SD) N Mean (SD) 
eGFR       
All visits     4.71 (1.54 to 7.89) 0.004 
3 months 191 53.7 (17.7) 193 57.7 (18.3) 5.03 (1.67 to 8.39) 0.003 
12 months 191 56.6 (19.6) 197 59.7 (20.4) 3.76 (0.02 to 7.51) 0.049 
24 months 188 53.7 (20.8) 194 57.4 (21.0) 4.27 (0.35 to 8.19) 0.033 
36 months 185 52.0 (21.8) 185 57.1 (22.4) 5.34 (1.17 to 9.51) 0.012 
48 months 179 50.2 (24.2) 177 55.3 (26.0) 5.38 (0.58 to 10.18) 0.028 
60 months 185 48.2 (25.0) 192 52.3 (25.5) 4.93 (0.06 to 9.80) 0.047 
       
  N (%) with 
outcome 





Graft loss 202 13 (6.4) 204 10 (4.9) 0.73 (0.32 to 1.67) 0.462 
Death 202 12 (5.9) 204 9 (4.4) 0.72 (0.30 to 1.70) 0.450 
Graft loss or death 202 25 (12.4) 204 19 (9.3) 0.72 (0.40 to 1.31) 0.278 
       
 Control (N=201) Late RIPC (N=205) Difference in means 
(95% CI)* 
P-value 
N Mean (SD) N Mean (SD) 
eGFR       
All visits     1.35 (-1.83 to 4.53) 0.405 
3 months 189 55.3 (17.8) 195 56.2 (18.4) 1.36 (-1.99 to 4.72) 0.426 
12 months 193 58.0 (20.7) 195 58.3 (19.5) 1.02 (-2.73 to 4.77) 0.594 
24 months 189 55.0 (20.7) 193 56.2 (21.2) 1.74 (-2.18 to 5.65) 0.385 
36 months 184 54.1 (21.5) 186 55.0 (23.1) 2.13 (-2.04 to 6.29) 0.317 
48 months 176 51.4 (26.1) 180 54.1 (24.3) 4.65 (-0.15 to 9.45) 0.058 
60 months 185 49.1 (26.4) 192 51.4 (24.3) 2.97 (-1.90 to 7.84) 0.232 
       
  N (%) with 
outcome 





Graft loss 201 11 (5.5) 205 12 (5.9) 1.04 (0.46 to 2.36) 0.923 
Death 201 13 (6.5) 205 8 (3.9) 0.58 (0.24 to 1.39) 0.219 
Graft loss or death 201 24 (11.9) 205 20 (9.8) 0.79 (0.43 to 1.42) 0.428 
       
* Early RIPC vs. Control / late RIPC vs control adjusted for baseline donor eGFR by CKD-EPI and factorial design 
** Early RIPC vs. Control / late RIPC vs control adjusted for factorial design 





















Figure 2 – Kaplan-Meier estimate of incidence of graft loss and mortality up to 5 years post-transplant, 
intention to treat analysis 
Panels show: A. graft loss early RIPC vs control; B. graft loss late RIPC vs control; C. mortality early RIPC vs 
control; and D. mortality late RIPC vs control. 
 
